Scope
ACG preventive care guidance treats cirrhosis follow-up as a structured programme spanning decompensation prevention, cancer surveillance, vaccination, nutrition, exercise and other health needs. Treatment eligibility matters: a surveillance or preventive drug recommendation should not be applied without its specified disease stage, previous event or therapeutic purpose. Most recommendations have low-certainty evidence, so this summary retains conditional wording and separates expert key concepts from graded recommendations.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Prevent encephalopathy with the appropriate strategy
- For cirrhosis with minimal hepatic encephalopathy, ACG conditionally suggests lactulose over no treatment, based on low-certainty evidence. When used to address symptoms, reassess adherence and improvement after 4–8 weeks to decide whether to continue. [1]
- After overt encephalopathy occurring while the patient is receiving lactulose, conditionally add rifaximin to reduce recurrence; evidence certainty is low. Continue the combination after discharge when indicated, and consider adding it for recurrent overt episodes in the outpatient setting. [1]
- Do not routinely substitute rifaximin for the minimal-encephalopathy prevention strategy: ACG conditionally suggests against its use solely as primary prevention of overt encephalopathy in cirrhosis with minimal encephalopathy. Improved short-term cognitive tests do not establish that prevention benefit. [1]
Prevent portal-hypertensive complications
- For high-risk oesophageal varices in cirrhosis, use carvedilol or endoscopic variceal ligation for primary bleeding prophylaxis. This is strong guidance with moderate certainty; choose according to tolerance, comorbidity and endoscopy access. High-risk features include large varices and/or red wale markings. [1]
- For primary prophylaxis of high-risk oesophageal varices in cirrhosis, the source describes carvedilol 12.5 mg/day, once daily or divided, with 6.25 mg if that dose is not tolerated but uncertain relative effectiveness. Withhold for symptomatic bradycardia; do not titrate to a pulse target, since portal effects are not determined by heart-rate reduction. [1]
- For cirrhosis with acute upper-GI bleeding, ACG conditionally suggests prophylactic antibiotics for 2–3 days rather than a longer course or no prophylaxis, with low certainty. This covers variceal and nonvariceal bleeding, with or without ascites; clinicians may extend treatment in those at higher infection risk. [1]
- In compensated cirrhosis with clinically significant portal hypertension, conditionally consider carvedilol to reduce first-episode ascites; evidence certainty is low. This population restriction matters: it is not a universal carvedilol prescription for every person with liver disease. [1]
- For cirrhotic ascites with paracentesis removing more than 5 L, the expert key concept advises albumin 6–8 g per litre removed to reduce circulatory dysfunction and kidney injury. For 5 L or less, benefit is less certain; reserve it for selected patients such as those with hyponatraemia or renal dysfunction. [1]
Offer surveillance to people who could benefit
- Perform liver ultrasound plus AFP every 6 months for HCC surveillance in cirrhosis when the person is a candidate for HCC therapy. This is strong, low-certainty guidance; suitable candidates include Child A/B and Child C on the transplant waitlist who are fit for and accept potential treatment. [1]
- ACG conditionally suggests against aspirin solely to prevent HCC, with very-low-certainty evidence. Do not start a statin solely for HCC chemoprevention either; this does not remove conventional cardiovascular indications for statin treatment in compensated cirrhosis. [1]
- Consider standard age-appropriate extrahepatic cancer screening for transplant candidates or for nonfrail patients with compensated cirrhosis without severe life-limiting comorbidity. Evidence is insufficient to recommend routine extrahepatic screening in decompensated cirrhosis outside the transplant waitlist. [1]
Check immunity and preventive vaccination
- Test hepatitis A immunity and vaccinate nonimmune patients with cirrhosis; ACG makes a strong recommendation with low-certainty evidence to prevent acute hepatitis. [1]
- Conditionally test for hepatitis B immunity and provide vaccination, with very-low-certainty evidence. Previously vaccinated but nonimmune patients should undergo revaccination; the expert key concept includes consideration of a Toll-like receptor 9 vaccine. [1]
- Recommend annual influenza vaccination and a SARS-CoV-2 primary series with consideration of boosters for patients with cirrhosis. These are strong recommendations despite low-certainty cirrhosis-specific evidence. [1]
- ACG recommends bivalent RSV vaccination in patients with cirrhosis aged 50 or over, with strong recommendation and low certainty. Apply this source-specific recommendation alongside local product authorisation and vaccination programmes. [1]
Combine nutrition, exercise and substance-use care
- Conditionally provide dietitian-guided nutrition with adequate calories and protein; evidence certainty is low. The source recommends protein 1.2–1.5 g/kg ideal body weight/day and energy 30–35 kcal/kg/day, with lower energy targets for obesity. Pair nutrition with exercise rather than relying on supplements alone. [1]
- For ambulatory patients with cirrhosis, conditionally suggest structured aerobic and resistance exercise to improve muscle health and physical function. Assess and monitor appropriately; trial evidence for nonambulatory patients and advanced decompensation is limited. [1]
- For active smokers with cirrhosis, recommend smoking-cessation counselling. ACG rates this strong despite low-certainty evidence because potential health benefits outweigh the small counselling burden. [1]
- Screen for alcohol use disorder with a validated tool such as AUDIT-C at clinical encounters, especially with deterioration or decompensation. Offer effective behavioural care and consider pharmacotherapy through integrated addiction/hepatology services or referral, tailored to local resources. [1]
Plan follow-up and treat osteoporosis
- After admission with cirrhosis and alcohol use disorder, conditionally arrange postdischarge behavioural therapy to reduce alcohol use; certainty is very low. Intensified follow-up before 14 days after a cirrhosis admission may reduce readmissions and mortality, alongside medication reconciliation, nutrition and other discharge support. [1]
- Conditionally treat osteoporosis in cirrhosis with bisphosphonates to reduce fracture risk; evidence certainty is low. Screen and use appropriate osteoporosis therapy; oesophageal or gastric varices alone are not a contraindication to an oral bisphosphonate. [1]
Limitations and use
- This preventive-care summary is not a complete protocol for acute bleeding, encephalopathy, infection, vaccine scheduling or individual drug dosing. Conditional recommendations require assessment of benefits, harms and patient preferences.
- The short prophylactic antibiotic course for upper-GI bleeding is the source's conditional recommendation; treatment of an established infection and higher infection risk require separate clinical assessment.
- US vaccine products and eligibility, nutrition services, surveillance access and drug availability need local adaptation in India. Screening remains appropriate only when its findings could change care.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Liver: Preventive Care for Patients With Cirrhosis
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.